XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.26

+0.9%

11:35 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (6647)	7/12/1998 8:26:00 PM
From: Robert S.	Read Replies (1) of 17367

Hello George. There is no denying that the BPI molecule is intriguing but it would be negligent to not discuss possible problems with this compound. The problem of BPI administration within a certain time frame may be an issue. While I am not aware of what this time frame is when applied to human patients, animal studies indicate that the sooner the BPI is administered, the better. Additionally, how effectively BPI neutralizes endotoxins may also be an issue. If BPI does not completely (100%) inactivate the endotoxins within the patient, does this not present an avenue for any remaining endotoxins to carry out their harmful effects?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next